
Mauro Gitto
@mauro_gitto
Followers
211
Following
490
Media
3
Statuses
90
MD, Research Fellow at @IcahnMountSinai Cardiology Resident at @HumanitasMilano
Milano, Lombardia
Joined November 2013
RT @Sticchi_Alex: A modern #PCI approach for #diffuse disease in a #calcific #LAD with a terrific final result!! Congrats @antocol171 @Dami….
0
10
0
RT @PCRonline: #EAPCI/PCR Journal Club: A randomised trial of sirolimus- versus paclitaxel-coated balloons for de novo coronary lesions. @m….
0
11
0
RT @ACCinTouch: The #ACCBOT has approved the College's newest officers and trustees who will assume their roles in March 2025 following #AC….
0
23
0
RT @leoneppmd: Fantastic opportunity to present new #DCB 3.0 registry data from @HumanitasMilano. Exciting sessions including:.- Everolimu….
0
4
0
Thrilled to present the results of our study on #DCB based LAD PCI at #TCT2023 in San Francisco and to see the full paper simultaneously published on @CircIntv.One more piece of evidence that supports the use of a #DCB based treatment for diffuse coronary artery disease.
DCB vs. DES for LAD PCI. A Featured Science Presentation @CRF #TCT2023 published simultaneously in @mauro_gitto @Sticchi_Alex @ChiaritoMauro @Antocol17 #TCTConference #ACCFIT #AHAJournals
1
3
19
Take a look at our comprehensive review just out on @MyJSCAI!. ➡️ @GGStefanini @alaide_chief @AlexandraLansky.
jscai.org
Dual antiplatelet therapy (DAPT) has been paramount in preventing thrombosis following percutaneous coronary intervention for nearly 3 decades. However, over the years, DAPT has seen significant...
Comprehensive guide to #DAPT in #PCI: past, present & future. Tailoring DAPT strategies to bleeding & ischemic risk. More to come on #ticagrelor #prasugrel in #ACS . ➡️. @AlexandraLansky @GGStefanini @mauro_gitto @alaide_chief
0
1
3
RT @RCMjournal: #RCM-Special Issue: Present and future of #tricuspid #regurgitation (1/5). 🚂Etiology, epidemiology, pathophysiology and man….
0
1
0
In the study by @MintenLennert, CAD presence and ⬆️ SS in TAVR candidates were associated with ⬆️ all-cause and CV death at 5y. However, PCI and completeness of revasc had no impact of mortality. Have a look at our editorial 👉 @GGStefanini @JACCJournals
1
6
19
Biochemical efficacy of #SGLT2 inhibitors by cardiovascular risk profile and volume status in a real-world diabetic population. Just accepted in @JCVPOnline. Take a look!
Benefits of SGLT2 inhibitors in a real-world diabetic population. .@mauro_gitto @GGStefanini @gcondorelli @HumanitasMilano @HUNIMED. #EMPA #CANVAS #DECLARE #SGLT2 #HbA1 #kidney #infection #glycemia #clinicaltrials #diabetes
0
0
1
RT @RoyTaoutel: Such a great honor to be part of this amazing trial! Check out our published work👇🏻 #WOMEN_FiRST @sealtin1 @mauro_gitto @Ya….
0
4
0
RT @SJcardio: Congrats @sealtin1 @mauro_gitto @RoyTaoutel on an important and timely publication . Wire free assessment always preferred w….
0
1
0
RT @sealtin1: Congratulations to our team @mauro_gitto @RoyTaoutel and the YCRG core lab for using novel QFR in women with stable coronary….
0
6
0
Comparison of #QCA, #QFR and visual assessment (VA) in #women with stable CAD:.-> ⬆️ %DS at VA vs. QCA.-> ⬆️ discrepancy observed in angiographically severe lesions .-> 1/3 of severe lesions at angiography had QFR >0.8. Read the full manuscript at
The integration of automated tools may provide a more accurate estimate of coronary stenosis in women with ischemic heart disease, research by @sealtin1 and @mauro_gitto in @InvasiveCardiol suggests. Learn about the WOMEN FiRST trial: @YaleMed @YaleIMed
1
3
9
RT @italian_cot: 🫀Left anterior descending coronary artery occlusion after balloon aortic valvuloplasty.Read at #ca….
0
4
0
RT @RCMjournal: 🎄🔊#RCM - Vol. 22 No. 4 (6/62).💎Review.#Etiology, #epidemiology, #pathophysiology and management of #TricuspidRegurgitation:….
0
6
0
TCT 208: ‘Accuracy of Quantitative Coronary Angiography and Visual Assessment for predicting functional significance of stenosis in women with chronic coronary syndrome’. Great team work! @sealtin1 @RoyTaoutel @YaleCardiology .@TCTConference #TCTConnect
1
2
8